NYMXF (Nymox Pharmaceutical) ROC %: -106.96% (As of Dec. 2024)

What is Nymox Pharmaceutical ROC %?

Nymox Pharmaceutical NYMXF +9.09% ROC % is -106.96% as of Dec. 2024.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Nymox Pharmaceutical's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was -106.96%.

As of today (2026-06-27), Nymox Pharmaceutical's WACC % is 0.00%. Nymox Pharmaceutical's ROC % is 0.00% (calculated using TTM income statement data). Nymox Pharmaceutical earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Nymox Pharmaceutical (OTCPK:NYMXF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Nymox Pharmaceutical's WACC % is 0.00%. Nymox Pharmaceutical's ROC % is 0.00% (calculated using TTM income statement data). Nymox Pharmaceutical earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Nymox Pharmaceutical ROC % Related Terms

Nymox Pharmaceutical ROC % Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical ROC % Chart

Nymox Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROC %

Get a 7-Day Free Trial

-2,472.57

-1,958.34

-1,364.51

-1,527.90

-212.08

Nymox Pharmaceutical Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Sep24	Dec24
ROC %	Get a 7-Day Free Trial															-807.34	-913.51	-4,992.29	-155.52	-106.96

Nymox Pharmaceutical ROC % Calculation

Nymox Pharmaceutical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

	ROC % (A: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2023 )	+	Invested Capital (A: Dec. 2024 ))	/ count )
=	-4.283 * ( 1 - 0% )	/	( (0.752	+	3.287)	/ 2 )
=	-4.283	/	2.0195
=	-212.08 %

where

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.627	-	3.05	-	( 0.07	-	max(0, 3.8	-	0.625	+	0.07	))
=	0.752

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.654	-	4.143	-	( 0.074	-	max(0, 7.429	-	0.653	+	0.074	))
=	3.287

Nymox Pharmaceutical's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-3.152 * ( 1 - 0% )	/	( (2.607	+	3.287)	/ 2 )
=	-3.152	/	2.947
=	-106.96 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.624	-	4.314	-	( 0.041	-	max(0, 6.92	-	0.623	+	0.041	))
=	2.607

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.654	-	4.143	-	( 0.074	-	max(0, 7.429	-	0.653	+	0.074	))
=	3.287

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -106.96% mean?

Nymox Pharmaceutical (NYMXF) has a ROC % of -106.96% as of Dec. 2024. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Nymox Pharmaceutical and its competitors.

Is Nymox Pharmaceutical's ROC % too high?

Nymox Pharmaceutical's current ROC % is -106.96%.

How does Nymox Pharmaceutical's ROC % compare to LYRA and RNAZ?

Nymox Pharmaceutical's ROC % of -106.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current ROC % is -106.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nymox Pharmaceutical stock overvalued right now?

Nymox Pharmaceutical (NYMXF) has a current ROC % of -106.96%. The current ROC % is -106.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current ROC % is -106.96% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Industry Healthcare Biotechnology

Comparable Companies LYRA RNAZ TOVX ADIL CDIO ACXP NKGN APRE KALA SLXN VRTX REGN ASX:CSL XKRX:207940 ALNY XBRU:UCB XBRU:ARGX INSM ONC XKRX:068270

Address Bay & Deveaux Streets, Nassau, BHS

Website https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.